H pylori eradication: a randomized prospective study of triple therapy with or without ecabet sodium.
OBJECTIVE
To investigate whether adding ecabet sodium to the standard triple therapy for H pylori infection improve eradication rate.


METHODS
Two hundred and fifty-seven H pylori-infected patients were randomly assigned to standard triple therapy (group A, n = 129) or triple therapy plus ecabet sodium (group B, n = 128). Successful eradication was defined as a negative (13)C-urea breath test 6-8 wk after completion of treatment.


RESULTS
After completion of therapy, 194/257 patients showed negative (13)C-urea breath test results. According to intention-to-treat analysis, the infection was eradicated in 93/129 (72.1%) patients in group A and 101/128 (78.9%) in group B (P = 0.204). Per-protocol analysis showed successful eradication in 93/118 (78.8%) patients from group A and 101/114 (88.6%) from group B (P = 0.044). There were no significant differences in the side effects experienced by the patients in the two treatment groups.


CONCLUSIONS
Our results suggest that the addition of ecabet sodium improves the efficacy of the standard triple therapy for H pylori.
Kim
Hyung Wook
HW
Department of Internal Medicine, Bongseng Memorial Hospital, Busan, Korea.
Kim
Gwang Ha
GH
Cheong
Jong Yun
JY
Yang
Ung Suk
US
Park
Seung Keun
SK
Song
Chul Soo
CS
Kang
Dae Hwan
DH
Song
Geun Am
GA
D045784:Abietanes / Q000494:pharmacology / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000494:pharmacology / Q000627:therapeutic use; D001944:Breath Tests; D004359:Drug Therapy, Combination; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D016896:Treatment Outcome
D045784:Abietanes; D000890:Anti-Infective Agents; D000897:Anti-Ulcer Agents; C061681:ecabet